drugset / Trial / NCT05535569
Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase Ib/II study to identify the recommended dose of paclitaxel and nivolumab for further study, and to assess the safety and clinical efficacy of this combined treatment in EBV-related, MSI-high, or PD-L1 positive advanced gastric cancer after first line treatment.
Timeline
- Start
- 2017-07-17
- Primary completion
- 2021-11-22
- Completion
- 2021-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Paclitaxel | Small molecule | 70 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
Indications
No indication recorded.